<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical azole treatments for otomycosis - Lee, A - 2021 | Cochrane Library</title> <meta content="Topical azole treatments for otomycosis - Lee, A - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009289.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical azole treatments for otomycosis - Lee, A - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009289.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009289.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical azole treatments for otomycosis" name="citation_title"/> <meta content="Ambrose Lee" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="ambrose.w.lee@gmail.com" name="citation_author_email"/> <meta content="James R Tysome" name="citation_author"/> <meta content="Cambridge University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Shakeel R Saeed" name="citation_author"/> <meta content="Royal Free Hampstead NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD009289.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009289.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009289.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009289.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Antifungal Agents [*administration &amp; dosage, adverse effects]; Bias; Clotrimazole [administration &amp; dosage, adverse effects]; Cycloheptanes [administration &amp; dosage, adverse effects]; Fluconazole [administration &amp; dosage, adverse effects]; Imidazoles [administration &amp; dosage, adverse effects]; Miconazole [administration &amp; dosage, adverse effects]; Otomycosis [*drug therapy]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009289.pub2&amp;doi=10.1002/14651858.CD009289.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009289\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009289\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009289.pub2",title:"Topical azole treatments for otomycosis",firstPublishedDate:"May 25, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009289.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009289.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009289.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009289.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009289.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009289.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009289.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009289.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009289.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009289.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>20854 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009289.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/appendices#CD009289-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/supinfo/CD009289StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/supinfo/CD009289StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical azole treatments for otomycosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information#CD009289-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ambrose Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information#CD009289-cr-0005">James R Tysome</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information#CD009289-cr-0006">Shakeel R Saeed</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information/en#CD009289-sec-0123">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009289.pub2">https://doi.org/10.1002/14651858.CD009289.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009289-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009289-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009289-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009289-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009289-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009289-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009289-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009289-abs-0001" lang="en"> <section id="CD009289-sec-0001"> <h3 class="title" id="CD009289-sec-0001">Background</h3> <p>Otomycosis is a fungal infection of the outer ear, which may be treated with topical antifungal medications. There are many types, with compounds belonging to the azole group ('azoles') being among the most widely used. </p> </section> <section id="CD009289-sec-0002"> <h3 class="title" id="CD009289-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of topical azole treatments for otomycosis.</p> </section> <section id="CD009289-sec-0003"> <h3 class="title" id="CD009289-sec-0003">Search methods</h3> <p>The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The search date was 11 November 2020. </p> </section> <section id="CD009289-sec-0004"> <h3 class="title" id="CD009289-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in adults and children with otomycosis comparing any topical azole antifungal with: placebo, no treatment, another type of topical azole or the same type of azole but applied in different forms. A minimum follow‐up of two weeks was required. </p> </section> <section id="CD009289-sec-0005"> <h3 class="title" id="CD009289-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were: 1) clinical resolution as measured by the proportion of participants with complete resolution at between two and four weeks after treatment (however defined by the authors of the studies) and 2) significant adverse events. Secondary outcomes were 3) mycological resolution and 4) other less serious adverse effects. We used GRADE to assess the certainty of evidence for each outcome. </p> </section> <section id="CD009289-sec-0006"> <h3 class="title" id="CD009289-sec-0006">Main results</h3> <p>We included four studies with 559 participants from Spain, Mexico and India. Three studies included children and adults; one included only adults. The duration of symptoms was not always explicitly stated. Mycological resolution results were only reported in one study. The studies assessed two comparisons: one type of topical azole versus another and the same azole but administered in different forms (cream versus solution). </p> <p><b>A. Topical azoles versus placebo</b> </p> <p>None of the studies assessed this comparison.</p> <p><b>B. Topical azoles versus no treatment</b> </p> <p>None of the studies assessed this comparison.</p> <p><b>C. One type of topical azole versus another type of topical azole</b> </p> <p><i>i) Clotrimazole versus other types of azoles (eberconazole, fluconazole, miconazole)</i> </p> <p>Three studies examined clotrimazole versus other types of azoles. The evidence is very uncertain about the difference between clotrimazole and other types of azole in achieving complete clinical resolution at four weeks (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.59 to 1.07; 3 studies; 439 participants; very low‐certainty evidence). The anticipated absolute effects are 668 per 1000 for clotrimazole versus 835 per 1000 for other azoles. </p> <p>One study planned a safety analysis and reported no significant adverse events in either group. The evidence is therefore very uncertain about any differences between clotrimazole and other types of azole (no events in either group; 1 study; 174 participants; very low‐certainty evidence). </p> <p>Clotrimazole may result in little or no difference in mycological resolution at two weeks follow‐up (RR 1.01, 95% CI 0.96 to 1.06; 1 study; 174 participants; low‐certainty evidence) or in other (less serious) adverse events at two weeks follow‐up (36 per 1000, compared to 45 per 1000, RR 0.79, 95% CI 0.18 to 3.41; 1 study; 174 participants; very low‐certainty evidence). </p> <p><i>ii) Bifonazole cream versus bifonazole solution</i> </p> <p>One study compared bifonazole 1% cream with solution. Bifonazole cream may have little or no effect on clinical resolution at two weeks follow‐up when compared to solution, but the evidence is very uncertain (RR 1.07, 95% CI 0.73 to 1.57; 1 study; 40 ears; very low‐certainty evidence). Bifonazole cream may achieve less mycological resolution compared to solution at two weeks after the end of therapy, but the evidence for this is also very uncertain (RR 0.53, 95% CI 0.29 to 0.96; 1 study; 40 ears; very low‐certainty evidence). Five out of 35 patients sustained severe itching and burning from the bifonazole solution but none with the bifonazole cream (very low‐certainty evidence). </p> </section> <section id="CD009289-sec-0007"> <h3 class="title" id="CD009289-sec-0007">Authors' conclusions</h3> <p>We found no studies that evaluated topical azoles compared to placebo or no treatment. The evidence is very uncertain about the effect of clotrimazole on clinical resolution of otomycosis, on significant adverse events or other (non‐serious) adverse events when compared with other topical azoles (eberconazole, fluconazole, miconazole). There may be little or no difference between clotrimazole and other azoles in terms of mycological resolution. It may be difficult to generalise these results because the range of ethnic backgrounds of the participants in the studies is limited. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009289-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009289-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009289-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009289-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009289-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009289-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009289-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009289-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009289-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009289-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009289-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009289-abs-0002" lang="en"> <h3>Do azole medicines taken as a cream or drops work for treating otomycosis (a fungal ear infection)? </h3> <p><b>Key messages</b> </p> <p>Due to weak evidence, we do not know if:</p> <p>‐ azoles taken as a cream or drops are better than no treatment or a placebo (dummy) treatment; </p> <p>‐ some azoles are better at ending infections than others.</p> <p>There is a need for well‐conducted studies that investigate the risks and benefits of these treatments for otomycosis. </p> <p><b>What is otomycosis?</b> </p> <p>Otomycosis is an ear infection caused by micro‐organisms called fungi (related to yeast and mushrooms). It mostly affects people who live in warm or tropical areas. Otomycosis typically causes an itchy ear, and can also cause ear pain, hearing loss and a fluid (discharge) that comes out of the ear. </p> <p>Otomycosis can be treated with many different creams or drops that fight fungi and are applied to the ears (topical treatments). The most widely used of these come from a group of medicines called azoles. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out about the risks and benefits of using topical azoles to treat otomycosis. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared topical azole treatment against:</p> <p>‐ a placebo (dummy) treatment;</p> <p>‐ no treatment; or</p> <p>‐ other azole treatments.</p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found four studies that involved 559 people from Spain, Mexico and India. Three studies included children and adults, and one included only adults. </p> <p>The studies compared:</p> <p>‐ the topical azole 'clotrimazole' against a different topical azole (eberconazole, fluconazole or miconazole; three studies); and </p> <p>‐ the topical azole 'bifonazole' as a cream against bifonazole drops (one study).</p> <p>No studies compared topical azoles against a placebo or no treatment.</p> <p><i>Clotrimazole compared against other topical azoles</i> </p> <p>The evidence suggests that, 24 days after the start of the treatment, there may be little to no difference between clotrimazole and other topical azoles in: </p> <p>‐ the number of people whose ears were no longer infected with fungi;</p> <p>‐ the number of severe adverse (unwanted) effects, such as severe allergic reactions;</p> <p>‐ the number of non‐severe unwanted effects.</p> <p>The evidence is not robust enough for us to determine if clotrimazole:</p> <p>‐ is better than other topical azoles for ending otomycosis.</p> <p><i>Bifonazole cream compared against bifonazole drops</i> </p> <p>The evidence is not robust enough for us to compare the benefits and risks of bifonazole cream against bifonazole drops. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The main limitations of the evidence are that it relies on few studies that:</p> <p>‐ sometimes have conflicting results;</p> <p>‐ are conducted in a few countries only; and</p> <p>‐ are conducted in ways that may have introduced errors into their results.</p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to November 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009289-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009289-sec-0109"></div> <h3 class="title" id="CD009289-sec-0110">Implications for practice</h3> <section id="CD009289-sec-0110"> <p>It is not possible to ascertain whether topical azoles are more effective than placebo or no treatment for otomycosis as no studies have assessed these comparisons. It is also not possible to say whether clotrimazole is more effective than other topical azoles in achieving clinical resolution of otomycosis due to the very low certainty of the evidence. The evidence is very uncertain about the effects of clotrimazole in achieving clinical resolution of otomycosis at four weeks follow‐up, as well as on outcomes including significant adverse events or other (non‐severe) adverse events, when compared to other azoles. The evidence suggests that clotrimazole results in little to no difference in mycological resolution compared to other topical azoles. It is very uncertain if bifonazole cream is more effective in achieving clinical resolution compared to bifonazole solution. Bifonazole cream may reduce the mycological cure rate compared to bifonazole solution but the evidence remains very uncertain. </p> </section> <h3 class="title" id="CD009289-sec-0111">Implications for research</h3> <section id="CD009289-sec-0111"> <p>The results of this review, current to 11 November 2020, show that there is a paucity of evidence comparing one type of azole versus placebo, no treatment or another type of azole. The very low‐certainty evidence in this review needs to be addressed in future updates of this topic. Potential adverse events were not well reported and the impact of confounding factors such as user compliance and water exposure are also unclear. </p> <section id="CD009289-sec-0112"> <h5 class="title">Suggestions for future trials</h5> <p>We propose key features of future research into azoles in the treatment of otomycosis as follows: </p> <section id="CD009289-sec-0113"> <h6 class="title">Design and methods</h6> <p> <ul id="CD009289-list-0015"> <li> <p>Randomised controlled trials should be analysed and reported by person (not by ear).</p> </li> <li> <p>In patients with bilateral otomycosis, and for outcomes that can be reported by ear such as clinical resolution, only one finding should be reported per person to avoid double counting. </p> </li> <li> <p>Appropriate methods must be reported for randomisation and allocation concealment to avoid selection bias, with adequate statistical power. </p> </li> <li> <p>Blinding of participants and assessors is preferable. In cases where blinding of participants/clinicians is not possible, efforts should be made to blind the members of staff responsible for outcome assessment and data analysis. </p> </li> </ul> </p> </section> <section id="CD009289-sec-0114"> <h6 class="title">Population</h6> <p> <ul id="CD009289-list-0016"> <li> <p>Diagnosis of otomycosis should be according to standardised criteria and be otoscopically and mycologically confirmed. </p> </li> <li> <p>If patients from 'high‐risk' groups are included they should be accounted for and explored in the design of the study via sensitivity analyses. </p> </li> </ul> </p> </section> <section id="CD009289-sec-0115"> <h6 class="title">Interventions</h6> <p> <ul id="CD009289-list-0017"> <li> <p>Future research should compare azoles versus placebo, no treatment or aural toileting alone. </p> </li> <li> <p>It should also allow for subgroup analyses on the various types of formulation, e.g. cream versus solution. Subgroup analyses should also be carried out for aural toileting as there is insufficient evidence in the literature to suggest that aural toileting is beneficial when used either alone or in combination with other treatment modalities, for example in the management of chronic suppurative otitis media (<a href="./references#CD009289-bbs2-0035" title="BhuttaM , HeadK , ChongL , DawJ , SchilderA , BurtonM , et al. Aural toilet (ear cleaning) for chronic suppurative otitis media. Cochrane Database of Systematic Reviews2020, Issue 9. Art. No: CD013057. [DOI: 10.1002/14651858.CD013057.pub2]">Bhutta 2020</a>). </p> </li> <li> <p>There should be clear reporting of the therapies used including frequency and duration, and clear descriptions of adjunctive therapies such as aural toileting. </p> </li> </ul> </p> </section> <section id="CD009289-sec-0116"> <h6 class="title">Outcomes</h6> <p> <ul id="CD009289-list-0018"> <li> <p>There are currently no standardised outcomes and definitions for otomycosis trials, and these are urgently needed. It would allow for ease of analysis and comparison of data across trials. </p> </li> <li> <p>Outcome assessment should include follow‐up mycological cultures.</p> </li> <li> <p>The assessment of adverse effects should be defined in the protocol and these should be systematically sought during the trials. </p> </li> <li> <p>Studies should follow up patients for at least six months or longer to identify the rate of relapse. </p> </li> <li> <p>Trials should be registered in a regional or international clinical trials registry and when published adhere to reporting guidelines such as CONSORT (<a href="./references#CD009289-bbs2-0038" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332.">CONSORT 2010</a>). </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009289-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009289-sec-0008"></div> <div class="table" id="CD009289-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Clotrimazole compared to another azole for otomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Clotrimazole compared to another azole for otomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> patients with otomycosis<br/><b>Setting:</b> ENT clinics<br/><b>Intervention:</b> clotrimazole<br/><b>Comparison:</b> another azole </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another azole</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with clotrimazole</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete clinical resolution</p> <p>Follow‐up: range 2 to 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.59 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is very uncertain whether there is a difference between clotrimazole and other azoles at achieving complete clinical resolution at 4 weeks. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>835 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>668 per 1000<br/>(492 per 1000 to 893 per 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant adverse events</p> <p>Follow‐up: 24 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The only study that mentioned significant adverse events reported that there were no events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to the lack of events and low number of participants it is very uncertain whether there is a difference between the groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological resolution</p> <p>Follow‐up: 24 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.96 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>174<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clotrimazole may result in little or no difference in mycological outcomes at 24‐day follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>966 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>976 per 1000<br/>(928 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Other adverse events</p> <p>Follow‐up: 24 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/>(0.18 to 3.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>174<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is very uncertain whether there is a difference between clotrimazole and other azoles in non‐significant adverse events at 24 days follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 153) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded to very low‐certainty evidence: downgraded by one level due to study limitations (risk of bias) because there was unclear allocation concealment, attrition bias and selective reporting bias. Downgraded by one level for inconsistency (heterogeneity of results; I<sup>2</sup> = 86%). Downgraded by one level for imprecision (confidence interval includes the possibility of both no difference and a substantial reduction in clinical resolution with clotrimazole). </p> <p><sup>2</sup>Downgraded to low‐certainty evidence. Downgraded by one level for indirectness (participants under 18 years old were excluded). Downgraded by two levels for imprecision (small sample size and no events reported, therefore unable to calculate an effect size). </p> <p><sup>3</sup>Downgraded to low‐certainty evidence. Downgraded by one level for indirectness (participants under 18 years old were excluded). Downgraded by one level for imprecision (small sample size). </p> <p><sup>4</sup>Downgraded to very low‐certainty evidence. Downgraded by one level for indirectness (participants under 18 years old were excluded). Downgraded by two levels for imprecision (low number of events, small sample size and very wide confidence intervals that include the possibility of either substantial benefit or substantial harm). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009289-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009289-sec-0009"></div> <section id="CD009289-sec-0010"> <h3 class="title" id="CD009289-sec-0010">Description of the condition</h3> <p>Otomycosis is a term used to describe a superficial fungal infection of the external ear canal. It has a reported worldwide incidence of between 5% and 80% (<a href="./references#CD009289-bbs2-0041" title="GharaghaniM , SeifiZ , Zarei MahmoudabadiA . Otomycosis in Iran: a review. Mycopathologia2015;179(5-6):415-24.">Gharaghani 2015</a>; <a href="./references#CD009289-bbs2-0055" title="MunguiaR , DanielS . Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otolaryngology2008;72(4):453-9.">Munguia 2008</a>). It is common in tropical countries and patients typically present with localised pruritis (itchiness) of the ear canal. Ear pain, hearing loss and discharge can also occur. Symptoms can be exacerbated if the ear canal skin is manipulated. Otomycosis is often seen in patients who have been treated for bacterial otitis externa with multiple course of topical antibiotic ear drops. </p> <p>The prevalence of otomycosis amongst those with pre‐existing inflammatory conditions of the ear, such as eczema and psoriasis, ranges from 9% to 30.4% (<a href="./references#CD009289-bbs2-0046" title="HoT , VrabecJT , YooD , CokerNJ . Otomycosis: clinical features and treatment implications. Otolaryngology - Head and Neck Surgery2006;135(5):787-91.">Ho 2006</a>; <a href="./references#CD009289-bbs2-0052" title="KurnatowskiP , FilipiakA . Otomycosis: prevalence, clinical symptoms, therapeutic procedures. Mycoses2001;44:472-9.">Kurnatowski 2001</a>). It is seen in all age groups and amongst those who participate in aquatic sports. It is known to increase during the summer months (<a href="./references#CD009289-bbs2-0059" title="RowlandsS , DevaliaH , SmithC , HubbardR , DeanA . Otitis externa in UK general practice: a survey using the UK General Practice Research Database. British Journal of General Practice2001;51(468):533-8.">Rowlands 2001</a>). More importantly, this disease has been linked to the extensive use of topical antibiotics for the treatment of otitis media and otitis externa (infection of the outer ear) (<a href="./references#CD009289-bbs2-0055" title="MunguiaR , DanielS . Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otolaryngology2008;72(4):453-9.">Munguia 2008</a>). In a Nepalese cross‐sectional study the prevalence of otomycosis was reported to be 23%. Of the 440 patients studied with otorrhoea (ear discharge), otalgia (ear pain) and canal pruritis (itchiness of the ear canal), 100 showed positive fungal cultures (<a href="./references#CD009289-bbs2-0057" title="PradhanB , TuladharN , AmatyaR . Prevalence of otomycosis in outpatient Department of Otolaryngology in Tribhuvan University Teaching Hospital, Kathmandu, Nepal. Annals of Otology, Rhinology and Laryngology2003;112:384-7.">Pradhan 2003</a>). Children with nutritional deficiency may be more susceptible to otomycosis (<a href="./references#CD009289-bbs2-0040" title="EnweaniI , IgumborH . Prevalence of otomycosis in malnourished children in Edo State, Nigeria. Mycopathologia1998;140:85-7.">Enweani 1998</a>). </p> <p>Diagnosis of otomycosis is based on clinical grounds and should be suspected in patients with pruritic and/or discharging ear canals and fungal elements seen on otomicroscopy. However, while there are similarities in clinical presentation between otomycosis and acute otitis externa their treatments are different (<a href="./references#CD009289-bbs2-0050" title="KaushikV , MalikT , SaeedS . Interventions for acute otitis externa. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD004740. [DOI: 10.1002/14651858.CD004740.pub2]">Kaushik 2010</a>). The prolonged usage of topical antibiotics alters the local flora of the ear canal leading to fungal proliferation and otomycosis. Patients with otomycosis often seek the advice of ENT specialists when their condition becomes unrelenting despite multiple courses of topical antibiotics. The role of the ENT specialist is to establish the correct diagnosis and prescribe the most appropriate treatment. This may include topical antifungals as well as suction clearance and dry mopping of debris. The recurrence rates of this disease vary according to the presence of the risk factors listed above. </p> <p>Both environmental and host factors may predispose people to otomycosis (<a href="./references#CD009289-bbs2-0050" title="KaushikV , MalikT , SaeedS . Interventions for acute otitis externa. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD004740. [DOI: 10.1002/14651858.CD004740.pub2]">Kaushik 2010</a>; <a href="./references#CD009289-bbs2-0055" title="MunguiaR , DanielS . Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otolaryngology2008;72(4):453-9.">Munguia 2008</a>). Environmental factors include moisture (leading to skin maceration, elevation of ear canal pH and diminution of cerumen, which protects the ear canal), trauma to the ear canal and high ambient temperatures. Host factors include open and wet mastoid cavities, the presence of excessive cerumen, an immunocompromised state, pregnancy, hearing aids with an occlusive mould, secondary bacterial otitis externa, increased use of topical antibiotics and swimming in pools. </p> <p>Many species of fungi have been identified as the cause of otomycosis. The two most common species are <i>Aspergillus niger</i> and <i>Candida albicans</i>. Controversy exists regarding the importance of identifying the causal agent(s) prior to treatment. While some clinicians believe it is good practice to use the appropriate treatment based on swab results to establish the sensitivity to antifungal agents (<a href="./references#CD009289-bbs2-0034" title="BassiounyA , KamelT , MoawadM , HindawyD . Broad spectrum antifungal agents in otomycosis. Journal of Laryngology and Otology1986;100:867-73.">Bassiouny 1986</a>), others advocate empirical treatment without testing for sensitivity (<a href="./references#CD009289-bbs2-0036" title="BlythC , PalasanthiranP , O'BrienT . Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics2007;119:772-84.">Blyth 2007</a>). </p> <p>In patients who are immunocompromised, an invasive and life‐threatening form of fungal infection may develop, known as skull base osteomyelitis or malignant otitis externa (<a href="./references#CD009289-bbs2-0037" title="BlythC , GomesL , SorrellT , da CruzM , SudA , ChenSC . Skull-base osteomyelitis: fungal vs. bacterial infection. Clinical Microbiology and Infection2011;17(2):306-11.">Blyth 2011</a>). This results in destruction of the underlying bone of the external ear canal and spreads along the skull base to involve the lower cranial nerves. Symptoms may include intense ear pain, persistent discharge, facial palsy, deafness, hoarseness and dysphagia. This condition should be distinguished from otomycosis and is not the focus of this review. </p> </section> <section id="CD009289-sec-0011"> <h3 class="title" id="CD009289-sec-0011">Description of the intervention</h3> <p>There are at least six main classes of drugs for the treatment of fungal infections: azoles, polyenes, nucleoside analogues, echinocandins, antiseptics and hydroxyquinolines (<a href="#CD009289-tbl-0002">Table 1</a>). In this review we focus on topical azoles due to their wide availability, low risk of ototoxicity and low rates of antifungal drug resistance. Examples include bifonazole, clotrimazole, eberconazole, fluconazole and miconazole. Clotrimazole is the most widely used topical azole. It can be dispensed as a 1% lotion or a topical cream, with the duration of treatment ranging from a few days to four weeks. Side effects are often localised and limited to skin redness and burning. Clotrimazole has a reported rate of effectiveness in otomycosis that ranges from 50% to 100% (<a href="./references#CD009289-bbs2-0048" title="JackmanA , WardR , AprilM , BentJ . Topical antibiotic induced otomycosis. International Journal of Pediatric Otolaryngology2005;69(6):857-60.">Jackman 2005</a>; <a href="./references#CD009289-bbs2-0049" title="JadhavVJ , PalM , MishraGS . Etiological significance of Candida albicans in otitis externa. Mycopathologia2003;156:313-5.">Jadhav 2003</a>). Topical azoles can also be used in cases of perforated ear drums (<a href="./references#CD009289-bbs2-0062" title="VennewaldI , KlemmE . Otomycosis: diagnosis and treatment. Clinics in Dermatology2010;28(2):202-11.">Vennewald 2010</a>). </p> <div class="table" id="CD009289-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of agents used to treat fungal infections</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Class of antifungals</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Examples</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mechanism of action</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bifonazole, clotrimazole, eberconazole, fluconazole, miconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits the synthesis of ergosterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyenes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nystatin, amphotericin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interacts with fungal membrane sterols</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nucleoside analogues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flucytosine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits macromolecular synthesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Echinocandins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caspofungin, micafungin, anidulafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits fungal cell wall synthesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antiseptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boric acid, gentian violet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydroxyquinolines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clioquinol (in Locacorten‐Vioform)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits fungal cell wall synthesis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>From <a href="./references#CD009289-bbs2-0055" title="MunguiaR , DanielS . Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otolaryngology2008;72(4):453-9.">Munguia 2008</a>. </p> </div> </div> <p>During treatment for otomycosis it is also common practice to remove the debris from the ear canal. This is known as aural toileting and it is administered with microsuction or dry mopping just prior to application of the topical remedy. It is considered to be standard therapy in most ENT outpatient clinics and an important adjunctive treatment (<a href="./references#CD009289-bbs2-0054" title="MofattehM , YazdiZ , YousefiM , NamaeiM . Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Brazilian Journal of Otorhinolaryngology2018;84(4):404-9.">Mofatteh 2018</a>). In this review we planned to explore the effects of aural toileting in subgroup analysis. </p> </section> <section id="CD009289-sec-0012"> <h3 class="title" id="CD009289-sec-0012">How the intervention might work</h3> <p>Azole antifungal drugs (with the exception of abafungin) inhibit the enzyme lanosterol 14 α‐demethylase, which is the enzyme necessary to convert lanosterol to ergosterol. Depletion of ergosterol in the fungal membrane disrupts the structure and many of its functions leading to inhibition of fungal growth (<a href="./references#CD009289-bbs2-0060" title="SheehanD , HitchcockC , SibleyC . Current and emerging azole antifungal agents. Clinical Microbiology Reviews1999;12:40-79.">Sheehan 1999</a>). It has been shown to have a potent in vitro broad‐spectrum fungicidal activity including against <i>Aspergillus</i> and <i>Candida</i> species, which are common agents in otomycosis (<a href="./references#CD009289-bbs2-0061" title="SternJ , ShahM , LucenteF . In vitro effectiveness of 13 agents in otomycosis and review of the literature. Laryngoscope1988;98:1173-7.">Stern 1988</a>). </p> <p>Although there is no general consensus as to the duration of topical azole therapy, two weeks appears to be common (<a href="./references#CD009289-bbs2-0051" title="KhanF , MuhammadR , MuhammadRK , RehmanF , IqbalJ , KhanM , et al. Efficacy of topical clotrimazole in treatment of otomycosis. Journal of Ayub Medical College, Abbottabad2013;25(1-2):78-80.">Khan 2013</a>). </p> </section> <section id="CD009289-sec-0013"> <h3 class="title" id="CD009289-sec-0013">Why it is important to do this review</h3> <p>Otomycosis is a common condition with a significant health and financial burden. An intervention found to be effective based on good evidence could have an impact globally. Although many treatment options are available clinicians continue to struggle with the most appropriate treatment option (<a href="./references#CD009289-bbs2-0055" title="MunguiaR , DanielS . Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otolaryngology2008;72(4):453-9.">Munguia 2008</a>). Evidence from Denmark has shown that there is wide variation in how this condition is treated by ENT consultants (<a href="./references#CD009289-bbs2-0033" title="ArndalE , GladH , HomoeP . Large discrepancies in otomycosis treatment in private ear, nose and throat clinic in Denmark. Danish Medical Journal2016;63(5):1-5.">Arndal 2016</a>). Many cohort studies have been published that investigate the usage of clotrimazole in otomycosis, the majority of which have found it to be safe and effective (<a href="./references#CD009289-bbs2-0042" title="HamzaA , KhanQ , KhanM . Efficacy of topical clotrimazole in otomycosis. Pacific Journal of Medical and Health Sciences2011;5(4):738-40.">Hamza 2011</a>; <a href="./references#CD009289-bbs2-0051" title="KhanF , MuhammadR , MuhammadRK , RehmanF , IqbalJ , KhanM , et al. Efficacy of topical clotrimazole in treatment of otomycosis. Journal of Ayub Medical College, Abbottabad2013;25(1-2):78-80.">Khan 2013</a>). </p> <p>A Cochrane Review has examined a number of interventions for otitis externa but its focus was on bacterial infections of the ear canal and not otomycosis specifically (<a href="./references#CD009289-bbs2-0050" title="KaushikV , MalikT , SaeedS . Interventions for acute otitis externa. Cochrane Database of Systematic Reviews2010, Issue 1. Art. No: CD004740. [DOI: 10.1002/14651858.CD004740.pub2]">Kaushik 2010</a>). A set of guidelines published by the Infectious Disease Society of America has examined the treatment of aspergillosis, but this is a condition that is prevalent amongst the immunocompromised population and is most often disseminated with a high risk of morbidity and mortality, which is vastly different to otomycosis (<a href="./references#CD009289-bbs2-0063" title="WalshT , AnnissieE , DenningD , HerbrechtR , KontoyiannisD , MarrK , et al. Treatment of aspergillosis: Clinical Practice Guidelines of the Infectious Disease Society of America. Clinical Infectious Diseases2008;46:327-60.">Walsh 2008</a>). A recent systematic review compared the efficacy of clotrimazole versus flumethasone pivalate 0.02% and clioquinol 1% (Locacorten‐Vioform) for otomycosis and concluded that there was insufficient evidence to support either therapy (<a href="./references#CD009289-bbs2-0045" title="HerasymK , BonaparteJ , KiltyS . A comparison of Locacorten-Vioform and clotrimazole in otomycosis: a systematic review and one-way meta-analysis. Laryngoscope2016;126:1411-9.">Herasym 2016</a>). </p> <p>It is important that an effective treatment is found for otomycosis due to its worldwide prevalence and the accompanying disease burden. A few randomised controlled trials have been conducted, however performing a meta‐analysis may be difficult because the interventions assessed vary in each study. We are aware of studies that have compared clotrimazole with 3% boric acid, with an experimental compound known as G328 and with eberconazole (<a href="./references#CD009289-bbs2-0039" title="dela Paz CotaB , VegaP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12.">Cota 2018</a>; <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0056" title="NCT01547221. Effectiveness of 3% boric acid in 70% alcohol versus 1% clotrimazole solution in otomycosis patients. https://clinicaltrials.gov/show/NCT01547221 (first received 7 March 2012).">NCT01547221</a>). </p> <p>Topical azoles are widely available on prescription in many countries and they are thought to be well tolerated with few side effects (<a href="./references#CD009289-bbs2-0034" title="BassiounyA , KamelT , MoawadM , HindawyD . Broad spectrum antifungal agents in otomycosis. Journal of Laryngology and Otology1986;100:867-73.">Bassiouny 1986</a>). A systematic review of the current evidence to assess their effects in the treatment of otomycosis is therefore warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009289-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009289-sec-0014"></div> <p>To evaluate the benefits and harms of topical azole treatments for otomycosis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009289-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009289-sec-0015"></div> <section id="CD009289-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009289-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with a minimum follow‐up duration of two weeks from the start of treatment. </p> <p>We excluded the following study designs:</p> <p> <ul id="CD009289-list-0001"> <li> <p>Cross‐over studies (because uncomplicated otomycosis is a self‐limiting condition). Furthermore, it is anticipated that the carry‐over effect of clotrimazole treatment may be prolonged as this drug is typically administered for over two weeks. </p> </li> </ul> </p> </section> <section id="CD009289-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants of all ages with a diagnosis of otomycosis.</p> <p>We included studies that diagnosed otomycosis based on presentation, with symptoms including: ear pain, itchiness, discharge, fullness or hearing impairment with findings of ear discharge. Studies should describe the mycological criteria for confirmation using either direct microscopy or culture showing fungal spores or hyphae. </p> <p>We excluded studies that focused primarily on otitis externa and those with skull base osteomyelitis (also known as malignant otitis externa). For studies with a mixed group of participants (consisting of otitis externa and otomycosis), we planned to analyse them providing that they had more than 80% of patients with otomycosis. </p> </section> <section id="CD009289-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD009289-sec-0020"> <h5 class="title">Intervention</h5> <p>Topical azole antifungals. We did not set a limit on the dose, duration or frequency of administration. </p> </section> <section id="CD009289-sec-0021"> <h5 class="title">Control</h5> <p>Placebo, no intervention or another type of topical azole.</p> </section> <section id="CD009289-sec-0022"> <h5 class="title">Adjunctive treatment</h5> <p>Aural toileting is considered routine in the treatment of discharging ears in an outpatient clinic. It may consist of dry mopping, syringing or microsuction (hoovering). </p> <p>We planned the following main comparisons:</p> <p> <ul id="CD009289-list-0002"> <li> <p>topical azoles versus placebo;</p> </li> <li> <p>topical azoles versus no treatment;</p> </li> <li> <p>one type of topical azole versus another type of topical azole.</p> </li> </ul> </p> <p>We planned to include studies using aural toileting if this adjunctive treatment was administered equally in both the intervention and comparator groups. </p> <p>We excluded other agents used for treating otomycosis as a comparison as we expected that the majority of these studies would have used a heterogeneous mixture of agents and concentrations. Pooling of data under these circumstances would be problematic. </p> <p>We recorded details of the interventions including treatment concentration, mode of administration (cream, drops, powder), dose (mg, mL or other) and number of administrations per day. </p> </section> </section> <section id="CD009289-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p>We analysed the following outcomes, but did not use them as a basis for including or excluding studies. </p> <section id="CD009289-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009289-list-0003"> <li> <p>Clinical resolution as measured by the proportion of participants with complete resolution at between two and four weeks after treatment (however defined by the authors of the studies). </p> </li> <li> <p>Significant adverse events (e.g. severe topical allergic reaction).</p> </li> </ul> </p> </section> <section id="CD009289-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009289-list-0004"> <li> <p>Mycological resolution: eradication of pathogenic ear canal fungi as determined by mycological means (e.g. potassium hydroxide smear or fungal culture). </p> </li> <li> <p>Other adverse events: local irritation, hearing loss, mild allergic reaction.</p> </li> </ul> </p> <p>For all outcomes other than clinical resolution, the time point for assessment was final follow‐up, as defined by the study authors. </p> </section> </section> </section> <section id="CD009289-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions. The date of the search was 11 November 2020. </p> <section id="CD009289-sec-0027"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched for published, unpublished and ongoing studies in the following databases from their inception: </p> <p> <ul id="CD009289-list-0005"> <li> <p>the Cochrane ENT Register (searched via CRS Web 11 November 2020);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (searched via the Cochrane Register of Studies 11 November 2020); </p> </li> <li> <p>Ovid MEDLINE(R) Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 11 November 2020); </p> </li> <li> <p>Ovid EMBASE (1974 to 11 November 2020);</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database), <a href="http://lilacs.bversusalud.org" target="_blank">lilacs.bversusalud.org</a> (searched 11 November 2020); </p> </li> <li> <p>Web of Science (1945 to 11 November 2020);</p> </li> <li> <p>CNKI (searched via Google Scholar 1999 to 11 November 2020);</p> </li> <li> <p>ClinicalTrials.gov (searched via the Cochrane Register of Studies and <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> (searched 11 November 2020); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), <a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a> (searched 11 November 2020). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b. (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD009289-sec-0120">Appendix 1</a>. </p> </section> <section id="CD009289-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. In addition, the Information Specialist searched Ovid MEDLINE to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. The Information Specialist also ran non‐systematic searches of Google Scholar to retrieve grey literature and other sources of potential trials. </p> <p>We did not perform a separate search for adverse effects. We only considered those adverse effects described in the included studies. </p> <p>We attempted to contact original authors for clarification and further data if trial reports were unclear and we arranged translation of papers when needed. </p> </section> </section> <section id="CD009289-sec-0029"> <h3 class="title" id="CD009289-sec-0029">Data collection and analysis</h3> <section id="CD009289-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two independent review authors (AL and JT) assessed all titles and abstracts from the search and eliminated studies that clearly did not satisfy the inclusion criteria. For studies that appear to meet the inclusion criteria we obtained the full‐text reports to confirm eligibility. We resolved any differences by discussion and consensus, with the involvement of the third author for clinical and methodological input when necessary. We listed the reasons for exclusion in the <a href="./references#CD009289-sec-0130" title="">Characteristics of excluded studies</a> table. A study flow diagram (PRISMA) was provided to illustrate the process for selection of studies (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> </section> <section id="CD009289-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>AL and JT independently extracted data from each study report using specifically designed data extraction forms. We checked any discrepancies in the data extracted against the original reports and resolve any differences by consensus. We contacted the original study authors for clarification or missing data whenever possible. </p> <p>We recorded the following data from each of the included studies: general characteristics (type of study, year of study, citation data, number of patients included and their baseline characteristics and risk factors), potential sources of bias, fungal types, procedures (type of randomisation, inclusion criteria, protocol for follow‐up and assessment, protocol for therapy and control, and number of patients who dropped out of the study), outcome data (definitions, clinical signs and symptoms, adverse events, microbiological data) and authors' conclusions. If information or data were missing, we attempted to contact the study authors. </p> <p>Where possible we extracted data to allow an intention‐to‐treat analysis (i.e. the analysis should include all the participants in the groups to which they were randomly assigned irrespective of compliance or whether patients had received the treatment as planned). </p> <p>For clinical resolution we reported the results between two and four weeks after completion of the interventions. For all other outcomes the time point of assessment was final follow‐up as defined by the study authors. </p> <p>In addition to extracting pre‐specified information about study characteristics and aspects of methodology relevant to risk of bias, we extracted the following summary statistics for each trial and each outcome: </p> <p> <ul id="CD009289-list-0006"> <li> <p>For binary data: the number of participants experiencing an event and the number of patients assessed at the time point. </p> </li> <li> <p>For ordinal scale data: we planned to analyse data which appeared to be approximately normally distributed as continuous data or if the analysis that the investigators performed suggests parametric tests were appropriate. However, none of the included studies recorded any outcomes as continuous data. </p> </li> </ul> </p> <p>As regards extraction of data for adverse events, there were variations in how studies had reported these. For instance, one study made a distinction between 'otalgia' and 'ear discomfort' whilst another reported 'itching' and 'burning' as a combined outcome. Prior to the start of data extraction we had agreed to divide adverse events into significant ones including severe topical allergic reactions from 'others' such as local irritation, hearing loss or mild allergic reactions. We extracted data for significant complications as a composite outcome. If a study reported more than one complication and we could not distinguish whether these occurred in one or more participants we extracted data with the highest incidence to ensure that we did not provide an unduly conservative estimate of the complication rate. </p> </section> <section id="CD009289-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>AL and TJ independently undertook assessment of the risk of bias of the included trials as guided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>) for the following domains: </p> <p> <ul id="CD009289-list-0007"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We used the Cochrane 'Risk of bias' tool in RevMan 5.4 (<a href="./references#CD009289-bbs2-0058" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>), which involves describing each of these domains as reported in the trial and then assigning a judgement about the adequacy of each entry: low, high or unclear risk of bias. We provided evidence to support our assessments in 'Risk of bias' tables. </p> </section> <section id="CD009289-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised the effects of dichotomous outcomes (e.g. proportion of patients with clinical or mycological resolution) as risk ratios (RR) with confidence intervals (CIs). For each of the key outcomes that we presented in the 'Summary of findings' table, we also expressed the results as corresponding risk based on the pooled results and compared to the assumed risk as risk ratios with CIs. The assumed baseline risk was the average mean risk of the control groups in the included studies used as the 'study population' (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011993.pub2/full#CD011993-bbs2-0051" target="_blank">Handbook 2011</a>). </p> </section> <section id="CD009289-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the individual participant. However, there was one included study that compared two different modes of azole application as opposed to two different formulations. In that study the unit of randomisation was the ear (35 participants, 40 ears). We were unable to identify the specific response for individuals with bilateral disease, therefore we could not estimate the correlation in response between ears. However, as the number of participants with bilateral disease was relatively low, we presented the results as if there were no correlation between ears of the same individual. This will result in narrower confidence intervals than would be the case if appropriate adjustment for correlation could be accounted. In the study concerned, five out of 35 patients had bilateral disease of which two of the patients received the same treatment in both ears whereas the remainder were treated with an azole solution in one side and an azole cream on the other side. We did not include the data in our meta‐analysis. </p> <p>We analysed multiple‐intervention studies according to the guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, including all relevant groups and avoiding double‐counting of participants (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> </section> <section id="CD009289-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors via email whenever the outcome of interest was not reported, or if the methods of the study suggested that the outcome had been measured. We had planned to impute missing standard deviations from 95% CIs, but this was not necessary as none of our included studies reported any continuous outcomes. </p> </section> <section id="CD009289-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity by visually inspecting the forest plots in conjunction with the Chi<sup>2</sup> test, using a 5% level of statistical significance, and the I<sup>2</sup> statistic. The I<sup>2</sup> statistic describes the percentage of variability in effect estimates that is due to heterogeneity rather than sampling error (chance). A value greater than 50% usually suggests substantial heterogeneity (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> </section> <section id="CD009289-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We intended to create funnel plots if we were able to include sufficient studies (more than 10) for an outcome. In the event that asymmetry was observed, we would have conducted a more formal investigation. However, we included too few studies to construct a funnel plot. </p> </section> <section id="CD009289-sec-0038"> <h4 class="title">Data synthesis</h4> <p>AL entered data into Review Manager 5.3 (<a href="./references#CD009289-bbs2-0058" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> <p>If we found sufficient studies, we planned to undertake a quantitative analysis and present the data in forest plots. We planned to pool studies in a meta‐analysis using a fixed‐effect model if possible, or a random‐effects model if we found substantial clinical or methodological heterogeneity in the included studies or identified substantial statistical heterogeneity (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> <p>We anticipated that trialists would usually have determined their outcome measures on more than one occasion. In general, these assessment visits would fall into the following categories: early (e.g. half‐way through treatment), end‐of‐therapy (a day or so after the cessation of treatment), test‐of‐cure (around a week after treatment) or test‐of‐recurrence (a few weeks after treatment has finished). Trialists may vary in the number and timing of visits they choose. In order to make a fair comparison between trials it is important to compare outcome measures taken at similar times. We had therefore decided a priori that we would only perform pooling of data from different studies (meta‐analysis) for outcome measures taken at similar times. </p> <p>We carried out all analyses using Review Manager 5.3 (<a href="./references#CD009289-bbs2-0058" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). For dichotomous data, we analysed treatment differences as risk ratio (RR) calculated using the Mantel‐Haenszel method. We planned to analyse time‐to‐event data using the generic inverse variance method, but this was not required as we had no data of this type. For continuous outcomes, if all the data were from the same scale, we would have pooled mean values obtained at follow‐up with change outcomes and reported this as a mean difference. However, if the standardised mean difference had to be used as an effect measurement, we did not plan to pool change and endpoint data. In the event, we did not undertake any meta‐analysis of continuous outcomes as none of the selected studies reported this type of outcome. </p> </section> <section id="CD009289-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to explore the effects of aural toileting as an adjunctive treatment in subgroup analysis. However, this was not possible due to the low number of studies. We were also unable to distinguish participants based on the frequency of aural toileting as they all received this manoeuvre only once prior to the commencement of their study. </p> <p>We did not intend to perform subgroup analyses based on dosage because azole antifungals are topical medications applied over a very small surface area with similar mechanisms of action. Hence, we do not believe that this variation is clinically important. We also planned to consider the methodology and frequency of aural toileting (dry mopping) if there was remaining unexplained heterogeneity despite conducting the other subgroup analyses. </p> </section> <section id="CD009289-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analysis for the follow factors to determine whether the findings were robust to the decisions made in the course of identifying, screening and analysing the trials: </p> <p> <ul id="CD009289-list-0008"> <li> <p>risk of bias of included studies: excluding studies with high risk of bias, defined as a high risk of allocation concealment bias and a high risk of attrition bias (overall loss to follow‐up of over 20%); </p> </li> <li> <p>how outcomes were measured: we planned to investigate the impact of including data when the validity of the measurement was unclear. Unfortunately, none of the included studies appeared to use valid measurement tools, so we were not able to carry out this sensitivity analysis. </p> </li> </ul> </p> <p>If any of these investigations found a difference in the size of the effect or heterogeneity, we would have mentioned this in the <a href="#CD009289-sec-0077">Effects of interventions</a> section. </p> </section> <section id="CD009289-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Using the GRADE approach, two review authors (AL and JT) independently rated the overall certainty of evidence using the Guideline Development Tool (GDT) (<a href="http://www.guidelinedevelopment.org" target="_blank">www.guidelinedevelopment.org</a>). We had planned to do this for the following comparisons: </p> <p> <ul id="CD009289-list-0009"> <li> <p>topical azoles versus placebo;</p> </li> <li> <p>topical azoles versus no treatment;</p> </li> <li> <p>one type of topical azole versus another type of topical azole.</p> </li> </ul> </p> <p>In the event, we only had data to present a 'Summary of findings' table for the comparison of clotrimazole versus another type of azole. </p> <p>The certainty of evidence reflects the extent to which we are confident that an estimate of effect is correct and we applied this in the interpretation of results. There were four possible ratings: high, moderate, low and very low (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). A rating of high certainty of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low certainty implies that any estimate of effect obtained is very uncertain. </p> <p>The GRADE approach rates evidence from RCTs that do not have serious limitations as high certainty. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors: </p> <p> <ul id="CD009289-list-0010"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>imprecision; and</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>The outcomes selected for GRADE assessment were: clinical resolution as measured by the proportion of participants with complete resolution, significant adverse events (severe topical allergic reaction), mycological resolution and other adverse effects (local irritation, hearing loss, mild allergic reaction). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009289-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009289-sec-0042"></div> <section id="CD009289-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD009289-sec-0044"> <h4 class="title">Results of the search</h4> <p>The search retrieved a total of 913 references. This number was reduced to 609 after removal of duplicates. We screened the titles and abstracts and subsequently removed 574 references. We assessed 35 full texts for eligibility of which 21 records (20 studies) were discarded with reasons recorded in the review (<a href="#CD009289-sec-0062">Excluded studies</a>). There are four studies awaiting assessment, as we were unable to obtain the full text (<a href="./references#CD009289-sec-0131" title="">Characteristics of studies awaiting classification</a>). We identified four ongoing studies (five references). </p> <p>A flowchart of study retrieval and selection is provided in <a href="#CD009289-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009289-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Process for sifting search results and selecting studies for inclusion." data-id="CD009289-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Process for sifting search results and selecting studies for inclusion.</p> </div> </div> </div> <p>We also ran another search to identify any new systematic reviews and guidelines relating to our topic so their reference lists could be scanned for additional trials and referenced in this review, however this search came back empty. </p> </section> <section id="CD009289-sec-0045"> <h4 class="title">Included studies</h4> <p>We included four studies (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>; <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). The <a href="./references#CD009289-sec-0129" title="">Characteristics of included studies</a> table provides their further details. </p> <section id="CD009289-sec-0046"> <h5 class="title">Study design</h5> <p>Three studies were randomised, parallel‐group, two‐arm trials (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>; <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). One study was a randomised, parallel‐group, three‐arm trial (<a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>). </p> </section> <section id="CD009289-sec-0047"> <h5 class="title">Unit of randomisation</h5> <p>There were no cluster‐randomised trials. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> randomised participants by ear. However, it was explicitly stated that two of the patients with bilateral otomycosis were treated with bifonazole cream in both ears and the other three patients with bifonazole solution in one side and cream in the other. For the reasons stated in the <a href="#CD009289-sec-0015">Methods</a> section we did not include this study in our meta‐analysis but a narrative report is provided. </p> </section> <section id="CD009289-sec-0048"> <h5 class="title">Sample size</h5> <p>A total of 559 participants were recruited in the four studies. The breakdown is as follows: <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> (35); <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> (190); <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> (214); <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> (120). </p> </section> <section id="CD009289-sec-0049"> <h5 class="title">Location</h5> <p>Two studies were conducted in India (<a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). One study was conducted in Mexico (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>) and the remaining study in Spain (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>). </p> </section> <section id="CD009289-sec-0050"> <h5 class="title">Setting</h5> <p>All studies were conducted in the ENT departments of hospitals. However, it is not clear if they were done in secondary or tertiary care centres. One study was conducted across nine centres (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). </p> </section> <section id="CD009289-sec-0051"> <h5 class="title">Population</h5> <section id="CD009289-sec-0052"> <h6 class="title">Age and sex</h6> <p>The ages of participants are reported in the <a href="./references#CD009289-sec-0129" title="">Characteristics of included studies</a> table. One study excluded participants less than 18 years old (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). No study showed evidence of randomisation by age. All four studies included both males and females and the percentages of females ranged from 50% to 66%. </p> </section> <section id="CD009289-sec-0053"> <h6 class="title">Diagnosis</h6> <p>Otomycosis was the main diagnosis in all studies. This was diagnosed clinically with or without mycological confirmation. </p> </section> </section> <section id="CD009289-sec-0054"> <h5 class="title">Interventions</h5> <p>Details of the interventions and treatment durations together with any adjuvant treatment for each of the included studies are summarised in the <a href="./references#CD009289-sec-0129" title="">Characteristics of included studies</a> table. The treatment duration lasted between 7 and 21 days. One study did not explicitly state the duration of treatment for some of their interventional drugs but it appeared that treatment did not extend beyond two weeks (<a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>). </p> </section> <section id="CD009289-sec-0055"> <h5 class="title">Comparisons</h5> <p>The included studies all presented data for one comparison: one type of topical azole versus another type of topical azole. One study used the same azole in different formulations (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>), and the other three studies compared clotrimazole against various types of azoles (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). </p> </section> <section id="CD009289-sec-0056"> <h5 class="title">Outcomes</h5> <section id="CD009289-sec-0057"> <h6 class="title">Clinical resolution</h6> <p>All four studies reported clinical resolution as an outcome although there are significant variations in their definitions, methods of determination and timing of assessments. </p> </section> <section id="CD009289-sec-0058"> <h6 class="title">Significant adverse events</h6> <p>One study reported this outcome, in a qualitative manner (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>). </p> </section> <section id="CD009289-sec-0059"> <h6 class="title">Mycological resolution</h6> <p>Two studies reported this outcome although the definitions and the timing of performing myological cultures differed (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>). Two studies performed mycological confirmation at the start of the study but it was not repeated at follow‐up (<a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). </p> </section> <section id="CD009289-sec-0060"> <h6 class="title">Other adverse events (local irritation, hearing loss, mild allergic reaction)</h6> <p><a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> reported this outcome in a qualitative manner. <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> recorded their adverse events according to the preferred term and system organ class of the Medical Dictionary for Regulatory Activities (version 17.1) (<a href="./references#CD009289-bbs2-0053" title="Medical Dictionary for Regulatory Activities. http://meddra.org.">MedDRA</a>). None of the adverse events recorded in their study was significant. </p> </section> </section> <section id="CD009289-sec-0061"> <h5 class="title">Funding</h5> <p>One paper was funded by a grant from a pharmaceutical company: <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> had their research supported by Laboratorios Salvat A.S. </p> <p>The other three studies did not provide information regarding funding. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> acknowledged Bayer A.G. for supplying the medication for their study. </p> </section> </section> <section id="CD009289-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies after further review. We asked translators fluent in Russian and Mandarin, affiliated with Cochrane, to assist in the translation of studies that were published in their respective languages. Further details for the reasons for exclusion can be found in the <a href="./references#CD009289-sec-0130" title="">Characteristics of excluded studies</a> table. Their main reasons for exclusion were as follows (some studies have more than one reason to account for their exclusion): </p> <p> <ul id="CD009289-list-0011"> <li> <p>Not RCTs: <a href="./references#CD009289-bbs2-0005" title="AlbanoV . Contribution to the therapy of otomycosis. Annali di Laringologia, Otologia, Rinologia, Faringologia1966;65(4):521-9. [CRS:10899693]">Albano 1966</a>; <a href="./references#CD009289-bbs2-0009" title="CarratX , BordureP , DutroncH , LacherG , MalardO . Otomycosis. Revue de Laryngologie - Otologie - Rhinologie2001;122(2):137-43. [CRS:10899567]">Carrat 2001</a>; <a href="./references#CD009289-bbs2-0010" title="CojocaruI , AlterasI , DulamitaL . Some data on the treatment of otomycoses. Mykosen1970;13(5):243-6. [CRS: 10899680]">Cojocaru 1970</a>; <a href="./references#CD009289-bbs2-0016" title="KhamaganovaI , Piven'NP . Combined treatment of external auditory canal diseases in dermatological practice. Vestnik Otorinolaringologii2010;2:66-8. [CRS: 10899458] [PMID: 20527091]">Khamaganova 2010</a>; <a href="./references#CD009289-bbs2-0020" title="Pal'chunV , OgorodnikovD . The experience with the supervision and treatment of the patients presenting with external otitis. Vestnik Otorinolaringologii2012;2:53-6. [CRS: 10899420]">Pal'chun 2012</a>; <a href="./references#CD009289-bbs2-0023" title="WeiXM , LuL , GaoX . Effect observation of cleaning up the external auditory canal by otoendoscope combined with clotrimazole ointment in the treatment of pregnancy with otitis externa mycotica. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2018;32(2):134-7. [CRS:10899484]">Wei 2018</a>. </p> </li> <li> <p>Comparisons were non‐azoles: <a href="./references#CD009289-bbs2-0006" title="BeckC . Contribution to the therapy of otomycosis. Zeitschrift fur Laryngologie, Rhinologie, Otologie und ihre Grenzgebiete1969;48(2):119-23. [CRS:10899683]">Beck 1969</a>; <a href="./references#CD009289-bbs2-0007" title="BerjisN , OkhovatS , KoujaniZ , BaradaranS . Comparing the therapeutic effect of clotrimazole and tolnaftate in treating variety of fungal species producing otomycosis in Alzahra and Kashani Hospitals, Iran. Journal of Isfahan Medical School2012;29:164. [CRS:10899759.]">Berjis 2012</a>; <a href="./references#CD009289-bbs2-0008" title="BoncalonR , ArguayM , RamosR . A preliminary study on the efficacy of Plumeria acuminata (Kalachuchi) bark extract ointment versus clotrimazole cream in the treatment of otomycosis. Philippine Journal of Otolaryngology Head and Neck Surgery2009;24(1):5-8. [CRS: 10899322.]">Boncalon 2009</a>; <a href="./references#CD009289-bbs2-0011" title="delPalacioA , CuetaraMS , Lopez-SusoMJ , AmorE , GarauM . Randomized prospective comparative study: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis. Mycoses2002;45(8):317-28. [CRS: 10899300.]">del Palacio 2002</a>; <a href="./references#CD009289-bbs2-0012" title="Diaz-PavonGA , Jimenez-GarciaL , Munoz-EstradaVF , AguilarEC . Efficacy of clotrimazole versus tolnaftate in otomycosis treatment. Otolaryngology - Head and Neck Surgery2018;159 Suppl 1:265-6. [CRS:10899491]">Diaz‐Pavon 2018</a>; <a href="./references#CD009289-bbs2-0013" title="GordanaR , MirkoP , RadjenovicG , PopovicM . Castellani tintura rubra versus dexamethasone neomycin; an effective cure for external otitis. European Archives of Oto-rhino-laryngology2007;264(Suppl 1):S153-264. [CRS: 4146776]">Gordana 2007</a>; <a href="./references#CD009289-bbs2-0014" title="Jimenez-GarciaL , Celis-AguilarE , Diaz-PavonG , Munoz EstradaV , Castro-UrquizoA , Hernandez-CastilloN , et al. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial. Brazilian Journal of Otorhinolaryngology2020;86(3):300-7. [PMID: 30826311]">Jimenez‐Garcia 2019</a>; <a href="./references#CD009289-bbs2-0015" title="JoeimonJ , Dhinesh BabuK . Open randomized clinical study on otomycosis. Indian Journal of Pharmacology2006;38(1):86. [CRS: 10899319]">Joiemon 2006</a>; <a href="./references#CD009289-bbs2-0017" title="MalikA , MalikS , AslamM . Comparative efficacy of topical clotrimazole and 3% salicylic acid in otomycosis. Rawal Medical Journal2012;37(1):1-10. ">Malik 2012</a>; <a href="./references#CD009289-bbs2-0018" title="MofattehM , YazdiZ , YousefiM , NamaeiM . Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Brazilian Journal of Otorhinolaryngology2018;84:404-9. ">Mofatteh 2017</a>; <a href="./references#CD009289-bbs2-0019" title="Nunez NavarreteE , delConsuelo Diaz ElizaldeN . Otomycosis. Two therapeutic approaches [Otitis externa micotica. Dos esquemas terapeuticos]. Revista Médica del IMSS2000;38(6):467-72. ">Nunez Navarrete 2000</a>; <a href="./references#CD009289-bbs2-0020" title="Pal'chunV , OgorodnikovD . The experience with the supervision and treatment of the patients presenting with external otitis. Vestnik Otorinolaringologii2012;2:53-6. [CRS: 10899420]">Pal'chun 2012</a>; <a href="./references#CD009289-bbs2-0022" title="NCT01547221. Effectiveness of 3% boric acid in isopropyl alcohol versus 1% clotrimazole solution in otomycosis patients: a randomized controlled trial. http://clinicaltrials.gov/show/NCT01547221 (first received 7 March 2012). [CENTRAL: CN-00855127] RomsaithongS , TomanakanK , TangsawadW , ThanaviratananichS . Effectiveness of 3 per cent boric acid in 70 per cent alcohol versus 1 per cent clotrimazole solution in otomycosis patients: a randomised, controlled trial. Journal of Laryngology &amp; Otology2016;130(9):811-5. ">Romsaithong 2016</a>; <a href="./references#CD009289-bbs2-0024" title="ZhangH , GuL . Effect of fluconazole eye drops on otomycosis external. Practical Pharmacy and Clinical Remedies2010;13(6):461-2. [CRS: 10899325]">Zhang 2010</a>. </p> </li> <li> <p>Unable to procure full texts for review: <a href="./references#CD009289-bbs2-0025" title="BambuleJ , GrigoriuD . Otomycoses and their treatment. Mykosen. Supplement1978;1:82-6. [CRS:10899662.]">Bambule 1978</a>; <a href="./references#CD009289-bbs2-0026" title="Ben RejebA , JelloulN , KchirN , BouzaianeA , ZitounaMM , Ben RachidMS , et al. Otomycosis. Tunisie Medicale1984;62(5):381-4. [CRS:10899643.]">Ben Rejeb 1984</a>; <a href="./references#CD009289-bbs2-0027" title="HuC , ZhangJ , MinX . Efficacy of fluconazole ear drops in otomycosis external. West China Medical Journal2007;4:805-6. [CRS: 10899320]">Hu 2007</a>; <a href="./references#CD009289-bbs2-0028" title="RenY , ZhangQ , YuZ . Clinical analysis of external ear canal coating by otoendoscopy on otomycosis external with triamcinolone acetonide and econazole nitrate cream. Lin Chuang Er Bi Yan Hou Ke za Zhi [Journal of Clinical Otorhinolaryngology]2015;29(14):1304-5. [CRS: 10899361]">Ren 2015</a>. </p> </li> <li> <p>Intervention was suction clearance and azoles were used in both groups: <a href="./references#CD009289-bbs2-0021" title="RafiqueM , UdaipurwalaI , EhsanU . Suction cleaning of the external auditory canal in otomycosis: is it really helpful?Journal of the Liaquat University of Medical and Health Sciences2014;13(3):97-100. [CRS:10899341]">Rafique 2014</a>. </p> </li> </ul> </p> </section> <section id="CD009289-sec-0063"> <h4 class="title">Ongoing studies</h4> <p>Four studies were ongoing at the time of writing this review. We made multiple attempts to contact some of the study authors to obtain further information, however we did not receive any responses. Some details of these studies can be found in the <a href="./references#CD009289-sec-0132" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> <section id="CD009289-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD009289-fig-0002">Figure 2</a> for a 'Risk of bias' graph (our judgements about each risk of bias item presented as percentages across all included studies) and <a href="#CD009289-fig-0003">Figure 3</a> for a 'Risk of bias' summary (our judgements about each risk of bias item for each included study). </p> <div class="figure" id="CD009289-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009289-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009289-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009289-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009289-sec-0065"> <h4 class="title">Allocation</h4> <section id="CD009289-sec-0066"> <h5 class="title">Random sequence generation</h5> <p>We judged all studies to be of unclear risk of bias (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>; <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). Although all of them mentioned that their studies were randomised none provided clear information about how their random sequences were generated. <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> used a trained nursing assistant to group the patients randomly and <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> used random number tables with the division of patients based on odd versus even number lots. <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> used random permuted blocks with a block size of four without providing details of how the results were applied. None of the studies showed a significant imbalance between the treatment and comparison groups. </p> </section> <section id="CD009289-sec-0067"> <h5 class="title">Allocation concealment</h5> <p>We judged two studies to be at high risk of allocation concealment bias as neither of these studies described concealment of the allocation sequence (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>; <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>). We assessed <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> as being at unclear risk. This study did not describe the methods of allocation concealment. However, the similarity in the consistency and viscosity of the two drugs were likely to facilitate this process in an indirect way. </p> <p>We judged <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> as being at low risk of allocation concealment bias as the authors explicitly stated that the sponsor, participants, investigators and study personnel were blinded to treatment allocation. </p> </section> </section> <section id="CD009289-sec-0068"> <h4 class="title">Blinding</h4> <section id="CD009289-sec-0069"> <h5 class="title">Performance bias</h5> <p>We determined one study to be at high risk of performance bias. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> did not mention blinding and thus it can be assumed to be an open study. In addition, the treatment was given either as bifonazole cream or a solution, which would make blinding difficult to achieve. </p> <p>We determined two studies to be at unclear risk of bias. <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> made some effort to blind the participants and investigators and a trained nursing assistant was utilised to ensure blinding was carried out, but the clotrimazole and fluconazole were administered as solutions and miconazole was given as a cream with different consistency. Blinding under these circumstances would not be effective. <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> did not provide information on how they kept participants and their assessors blinded from the allocated treatments. </p> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> was deemed to be at low risk of bias as it explicitly stated that the sponsor, participants, investigators and study personnel were blinded to treatment allocation. </p> </section> <section id="CD009289-sec-0070"> <h5 class="title">Detection bias</h5> <p>Similar to performance bias, we assessed one study to be at high risk (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>), two studies to be at unclear risk (<a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>) and one study to be at low risk of detection bias (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). </p> </section> </section> <section id="CD009289-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>We deemed one study to be at high risk of attrition bias: <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> reported that 145 out of 214 enrolled in their study presented for their assessment at the end of the second week. The percentage of loss to follow‐up was 32%. </p> <p>We assessed the other three studies to be at low risk of attrition bias. Their loss to follow‐up rates were as follows: </p> <p> <ul id="CD009289-list-0012"> <li> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>: 12%; </p> </li> <li> <p><a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>: 10%; </p> </li> <li> <p><a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>: 0%. </p> </li> </ul> </p> <p>In particular, <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> stated that patient request was the most common reason for discontinuation in both treatment arms. </p> </section> <section id="CD009289-sec-0072"> <h4 class="title">Selective reporting</h4> <p>None of the studies had protocols identified through our searches of clinical trial registries. </p> <p>We assessed two studies to be at high risk of bias. <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> provided no information on the outcome of the 19 patients who did not return for follow‐up. Furthermore, some rudimentary mycological data were presented for the first follow‐up period even though the protocol did not mention that this was to be presented. <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> stated in their protocol that all patients were reviewed weekly for reduction in symptoms and signs. However, no follow‐up data on symptoms (and mycology) were presented. Both studies used assessment scales that were non‐standardised and open to subjective interpretation. </p> <p>One study was assessed as being at unclear risk of bias. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> did not provide definition as to what the outcomes constituted or how they were measured. However, all outcomes stated in the methodology section were reported. There were no statistics or P values reported. </p> <p>We assessed <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> to be at low risk of bias as the outcomes that were presented in their methods sections were well reported in the results section. </p> </section> <section id="CD009289-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <section id="CD009289-sec-0074"> <h5 class="title">Measurement bias</h5> <p>We assessed all four studies to be at unclear risk of measurement bias as they all used different Likert‐type scales without mentioning whether they had undergone statistical validation for internal consistency and test‐retest reliability. The study by <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> used a four‐point signs and symptoms scale with a global score obtained from the sum of each individual score for pruritis, otalgia, otorrhoea and aural fullness. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> used a similar scale for a variety of clinical parameters. <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> employed clinical examination and graded the responses as good, moderate and no response. <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> also used clinical examination (the detection of debris on microscopy) as the main factor to determine the response to treatment. </p> </section> <section id="CD009289-sec-0075"> <h5 class="title">Funding</h5> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> stated that "this work was supported by Laboratorios Salvat, S.A." The other three studies did not provide information on funding. </p> </section> <section id="CD009289-sec-0076"> <h5 class="title">Declarations of interest</h5> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> declared that the authors had no conflicts of interest, whilst the other three studies did not make any statement about interests. </p> </section> </section> </section> <section id="CD009289-sec-0077"> <h3 class="title" id="CD009289-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD009289-tbl-0001"><b>Summary of findings 1</b> Clotrimazole compared to another azole for otomycosis</a> </p> <section id="CD009289-sec-0078"> <h4 class="title">Topical azoles versus placebo</h4> <p>None of the included studies assessed this comparison.</p> </section> <section id="CD009289-sec-0079"> <h4 class="title">Topical azoles versus no treatment</h4> <p>None of the included studies assessed this comparison.</p> </section> <section id="CD009289-sec-0080"> <h4 class="title">One type of topical azole versus another type of topical azole</h4> <section id="CD009289-sec-0081"> <h5 class="title">1) Clotrimazole versus other azoles</h5> <p>We included three studies (524 participants) in this comparison. See <a href="./full#CD009289-tbl-0001">summary of findings Table 1</a>. </p> <p> <ul id="CD009289-list-0013"> <li> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> compared clotrimazole with eberconazole. </p> </li> <li> <p><a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> compared clotrimazole, miconazole and fluconazole (three‐arm trial). </p> </li> <li> <p><a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> compared clotrimazole with fluconazole. </p> </li> </ul> </p> <section id="CD009289-sec-0082"> <h6 class="title">Primary outcomes</h6> <section id="CD009289-sec-0083"> <p><b>Complete clinical resolution between two and four weeks after treatment</b></p> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> reported that slightly fewer participants receiving clotrimazole achieved clinical cure compared with eberconazole (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.82 to 1.12). </p> <p><a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> reported that fewer patients achieved clinical cure with clotrimazole drops compared to miconazole and fluconazole (RR 0.93, 95% CI 0.79 to 1.09). </p> <p><a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> reported that fewer patients achieved clinical cure with clotrimazole drops compared to fluconazole drops (RR 0.50 95% CI 0.35 to 0.71). </p> <p>We pooled the results of these studies in a meta‐analysis for this outcome (RR 0.80, 95% CI 0.59 to 1.07; 3 studies; 439 participants; I<sup>2</sup> = 86%; very low‐certainty evidence). It is very uncertain whether there is a difference between clotrimazole and other azoles at achieving complete clinical resolution at four weeks. </p> </section> <section id="CD009289-sec-0084"> <p><b>Significant adverse events</b></p> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> (n = 190) reported that there were no serious adverse events in either treatment group. Due to the low number of participants and events it is very uncertain whether there is a difference between the groups (very low‐certainty evidence). </p> </section> </section> <section id="CD009289-sec-0085"> <h6 class="title">Secondary outcomes</h6> <section id="CD009289-sec-0086"> <p><b>Mycological resolution</b></p> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> (n = 190) reported this outcome. The evidence suggests that clotrimazole results in little to no difference in mycological resolution at 24‐day follow‐up (RR 1.01, 95% CI 0.96 to 1.06; 1 study; 190 participants; low‐certainty evidence). </p> </section> <section id="CD009289-sec-0087"> <p><b>Other adverse events</b></p> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> (n = 190) reported this outcome. The evidence suggests that clotrimazole results in little to no difference in non‐significant adverse events (RR 0.79, 95% CI 0.18 to 3.41; 1 study; 190 participants; very low‐certainty evidence). The absolute effect was 9 fewer per 1000 (from 37 fewer to 108 more per 1000). </p> </section> </section> <section id="CD009289-sec-0088"> <h6 class="title">Subgroup analyses</h6> <p>No subgroup analyses were possible for this comparison:</p> <p> <ul id="CD009289-list-0014"> <li> <p>Aural toileting: all studies included aural toileting as a pre‐treatment.</p> </li> </ul> </p> </section> </section> <section id="CD009289-sec-0089"> <h5 class="title">2) One mode of application versus another mode of application of topical azole</h5> <p>One study compared different formulations of bifonazole as opposed to another type of azole <b>(</b><a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>). We did not include this study in our main comparison meta‐analysis for two reasons. First, we feel that comparing different formulations of the same azole is not the same as comparing one type of azole with another. Hence its inclusion would constitute a protocol violation. Secondly, the unit of randomisation in this study was the ear rather than the participant and we were unable to account appropriately for the correlation between ears amongst the participants with bilateral disease. Nevertheless we believe it is appropriate to include this study in our review since it is clinically relevant to compare the clinical efficacy of different formulations of the same drug in treating otomycosis (see <a href="#CD009289-sec-0127">Differences between protocol and review</a>). </p> <section id="CD009289-sec-0090"> <h6 class="title">Primary outcomes</h6> <section id="CD009289-sec-0091"> <p><b>Complete clinical resolution between two to four weeks after treatment</b></p> <p>The evidence suggests that bifonazole cream results in little to no difference in clinical resolution at two weeks after the end of therapy: 15/20 bifonazole cream (intervention); 14/20 bifonazole solution (comparator) (RR 1.07, 95% CI 0.73 to 1.57; very low‐certainty evidence). </p> </section> <section id="CD009289-sec-0092"> <p><b>Significant adverse events</b></p> <p>Five out of 35 patients sustained severe itching and burning from the bifonazole solution but none with the bifonazole cream: 5/20 ears in the solution group compared to 0/20 ears in the cream group (very low‐certainty evidence). </p> </section> </section> <section id="CD009289-sec-0093"> <h6 class="title">Secondary outcomes</h6> <section id="CD009289-sec-0094"> <p><b>Mycological resolution</b></p> <p>Bifonazole cream achieved less mycological resolution compared to bifonazole solution at two weeks after the end of therapy: 8/20 bifonazole cream; 15/20 bifonazole solution (RR 0.53, 95% CI 0.29 to 0.96, very low‐certainty evidence). </p> </section> <section id="CD009289-sec-0095"> <p><b>Other adverse events</b></p> <p>Twelve out of 35 patients (34%) sustained moderate itching and burning with bifonazole solution. No participants reported irritation with bifonazole cream on their treated side. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009289-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009289-sec-0096"></div> <section id="CD009289-sec-0097"> <h3 class="title" id="CD009289-sec-0097">Summary of main results</h3> <p>We included four studies in this review (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>; <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). All of these studies included patients with otomycosis as the main diagnosis. Due to the limited number of studies and the incomplete reporting of some outcomes we were unable to accumulate strong evidence for our comparisons. The reporting of adverse events was sub‐optimal, with only <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> using standardised methods in some of their reporting. </p> <section id="CD009289-sec-0098"> <h4 class="title">Topical azoles versus placebo</h4> <p>None of the included studies assessed this comparison.</p> </section> <section id="CD009289-sec-0099"> <h4 class="title">Topical azoles versus no treatment</h4> <p>None of the included studies assessed this comparison.</p> </section> <section id="CD009289-sec-0100"> <h4 class="title">One type of topical azole versus another type of topical azole</h4> <p><b>1) Clotrimazole versus other azoles</b> </p> <p>See <a href="./full#CD009289-tbl-0001">summary of findings Table 1</a>. </p> <p>Three studies compared one type or formulation of topical azole versus another (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>; <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>). They compared clotrimazole as one of their study drugs with other types of azoles, namely eberconazole, fluconazole and miconazole. In <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>, participants were given either eberconazole or clotrimazole solutions (five drops twice a day) for 14 consecutive days. <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> compared clotrimazole drops, miconazole cream and fluconazole drops with varying amounts and frequency of administration. More importantly, the duration of treatment was not explicitly stated. <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> compared clotrimazole drops with fluconazole (three drops thrice daily) for three weeks. All three studies employed some form of dry mopping as an adjunct treatment. </p> <p>It is very uncertain whether there is a difference between clotrimazole and other azoles at achieving complete clinical resolution at four weeks (RR 0.80, 95% CI 0.59 to 1.07; 3 studies; 439 participants; I<sup>2</sup> = 86%). We assessed the evidence to be of very low certainty. In terms of absolute effects the results for achieving clinical resolution at four weeks were: clotrimazole 668 per 1000 and other azoles 835 per 1000. </p> <p>Only one study recorded significant adverse events but reported none (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). </p> <p>With regards to mycological resolution at 24 days follow‐up, the evidence suggests that clotrimazole may result in little or no difference (RR 1.01, 95% CI 0.96 to 1.06). We downgraded the evidence for this outcome to low certainty due to indirectness (exclusion of participants under the age of 18) and imprecision (small sample size). Clotrimazole may result in little or no difference in other (less severe) adverse events at 24 days follow‐up (RR 0.79, 95% CI 0.18 to 3.41). We downgraded this outcome to very low certainty due to indirectness (exclusion of participants under the age of 18) and imprecision (very few events with a small sample size, and wide confidence intervals for the effect estimate). </p> <p><b>2) Bifonazole cream versus bifonazole solution</b> </p> <p>In <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>, it was reported that there was no difference in clinical resolution between bifonazole cream and solution at two weeks following the end of therapy. Bifonazole cream may reduce the mycological cure rate compared to the solution formulation (RR 0.53, 95% CI 0.29 to 0.96), but the evidence is very uncertain. Overall, we assessed the evidence from this single study to be of very low certainty due to study limitations (multiple risks of bias: allocation concealment, performance and detection bias), imprecision (small number of events with narrow confidence intervals) and indirectness (single‐centre study from one country limiting external validity). Therefore, it remains very uncertain indeed whether there is a difference between the two drug formulations in terms of these two outcomes. </p> </section> </section> <section id="CD009289-sec-0101"> <h3 class="title" id="CD009289-sec-0101">Overall completeness and applicability of evidence</h3> <p>We identified three studies that compared clotrimazole versus another type of azole and one study that compared two different formulations of application of the same drug, which fulfilled our inclusion criteria. However, this does not represent the entire spectrum of azoles used clinically and it would be difficult to extrapolate our results to those drugs. All of the included studies only recruited participants with otomycosis and most included adults and children. The only exception was <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>, which excluded participants below the age of 18 years. </p> <p>We stated a priori in our protocol that we would examine clinical resolution at two to four weeks follow‐up as one of our primary endpoints. We chose this endpoint as we felt that it is clinically more relevant than partial resolution. One of the studies used a clinical scale comprising data obtained from signs, symptoms and fungal culture (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). In order for participants to achieve clinical resolution they had to be asymptomatic and have a negative culture. However, <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> and <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> used the amount of debris build‐up as the sole indicator of clinical resolution. We felt this to be less robust, notwithstanding the subjectivity involved in the assessment of clinical responses. None of the papers mentioned that their assessment scales were pre‐tested to ensure good internal validity and test‐retest reliability. </p> <p>Data for a number of outcomes were missing. In particular, only <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> showed follow‐up fungal culture data at the end of their follow‐up period, defined as day 24. Mycological follow‐up results were not available in <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> or <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>. This makes the classification of treatment outcomes problematic. </p> <p>We considered compliance with treatment and water precautions to be two potentially confounding factors. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> was the only study that followed the participants daily during treatment whereas the other studies relied on home administration of the interventional drugs. No data were available on compliance with treatment. Swimming is known to be a risk factor in otomycosis (<a href="https://www.healthline.com/health/otomycosis#outlook" target="_blank">www.healthline.com/health/otomycosis#outlook</a>), however none of the studies reported data on patient compliance with water precautions. </p> <p>One limitation in our review involves the heterogeneity with which adverse events were reported in two studies (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>; <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>). In particular, <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> employed objective and stringent criteria in their safety analysis. Neither of these studies reported significant adverse effects. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> reported five patients with severe itching and burning with bifonazole solution yet all of these completed the full course of treatment. None of their participants developed adverse events with bifonazole cream and all of their adverse events were seen in patients who received bifonazole solution. Three patients with bilateral otomycosis developed intolerance only on the side treated with bifonazole solution. We considered the risk of double counting of adverse events and the risks of serious systemic toxicities to be low given that only 5 out of 35 patients had bilateral otomycosis and the interventions were all topically based. </p> <p>The length of follow‐up for three out of four studies was between one and four weeks. <a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a> was the only study that reported outcomes at two and a half years after treatment. Therefore there remains limited evidence regarding the long‐term effects of topical azoles for the resolution symptoms in patients with otomycosis. </p> <p>Out of the four studies, only <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> used statistical methods for their intention‐to‐treat population to impute their missing data. We considered the high dropout rate of 32% in one study to be problematic (<a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a>). </p> <p>The effect of aural toileting in the treatment of otomycosis remains unknown. It is a manoeuvre widely used in otolaryngology outpatient departments. All four of the studies that we analysed utilised it for all of their participants. We were therefore unable to perform a subgroup analysis. Aural toileting may have an impact on the treatment of chronic ear diseases from other infectious causes. In a recent Cochrane Review on the treatment of chronic suppurative otitis media (chronic infection of the middle ear with pus), the researchers noted in one of their comparisons that fewer patients receiving topical and oral antibiotics had resolution of their ear discharges compared with acetic acid and suction aural toileting (<a href="./references#CD009289-bbs2-0044" title="HeadK , ChongLY , BhuttaMF , MorrisPS , VijayasekaranS , BurtonMJ , et al. Antibiotics versus topical antiseptics for chronic suppurative otitis media. Cochrane Database of Systematic Reviews2020, Issue 1. Art. No: CD013056. [DOI: 10.1002/14651858.CD013056]">Head 2020</a>). However, in a related Cochrane Review the authors were very uncertain whether aural toileting has any effect in resolving ear discharge in patients with chronic suppurative otitis media (<a href="./references#CD009289-bbs2-0035" title="BhuttaM , HeadK , ChongL , DawJ , SchilderA , BurtonM , et al. Aural toilet (ear cleaning) for chronic suppurative otitis media. Cochrane Database of Systematic Reviews2020, Issue 9. Art. No: CD013057. [DOI: 10.1002/14651858.CD013057.pub2]">Bhutta 2020</a>). These authors also met with similar challenges to us in their analyses in terms of the paucity of data and the poor quality of evidence. More research into the effects of aural toileting in otomycosis is required. </p> <p>In certain parts of the world otomycosis is relatively rare. However, it can occur secondary to misuse of ototopical drugs for otitis externa or tympanostomy tube otorrhoea and can be treated with clotrimazole. There is no evidence to show that clotrimazole is ototoxic in experimental models or in clinical practice in children with tympanostomy tubes. Furthermore, a single application after microscopic debridement has been shown to cure fungal tympanostomy tube otorrhoea in most cases (<a href="./references#CD009289-bbs2-0047" title="IsaacsonG . Oxymetazoline, mupirocin, clotrimazole—safe, effective, off-label agents for tympanostomy tube care. Ear, Nose &amp; Throat Journal2020;99(1 Suppl):30S-4S.">Isaacson 2020</a>). </p> </section> <section id="CD009289-sec-0102"> <h3 class="title" id="CD009289-sec-0102">Quality of the evidence</h3> <p>In this review the overall certainty of the evidence assessed using GRADE for clotrimazole versus other azoles ranged from low to very low, with downgrading in the GRADE domains of study limitations (risk of bias), imprecision, inconsistency and indirectness (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> <section id="CD009289-sec-0103"> <h4 class="title">Study limitations (risk of bias)</h4> <p>We judged <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> to be the study least affected by biases. We considered the other three studies to be rife with selection and allocation biases as none of them reported methods of random sequence generation and measures to enhance blinding. In particular, <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> and <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> did not rely on fungal cultures as part of their determinants of the patients' response. This may have impacted on the accuracy of the diagnostic outcomes. <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> lowered the GRADE rating further because of the relatively high dropout rate of 32%. All of the studies faced a common challenge of not having a validated instrument to measure the clinical response of participants. </p> </section> <section id="CD009289-sec-0104"> <h4 class="title">Imprecision</h4> <p>For an estimate of imprecision we examined the sample size contributions of the included studies in combination with the confidence intervals from <a href="./full#CD009289-tbl-0001">summary of findings Table 1</a>. The included studies were small, with a mean sample size of 140. We were able to pool the results of three studies involving clotrimazole and provide an estimate of clinical resolution. The confidence interval ranges from 0.59 to 1.07. We were only able to draw our confidence intervals for the other outcomes of mycological cure and other adverse effects from one study (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). </p> </section> <section id="CD009289-sec-0105"> <h4 class="title">Inconsistency</h4> <p><a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> and <a href="./references#CD009289-bbs2-0003" title="NavaneethanN , DharmapuriR , KrishnanY . Type of antifungals: does it matter in empirical treatment of otomycosis?Indian Journal of Otolaryngology, and Head, and Neck2014;67(1):64-7. [DOI: 10.1007/s12070-014-0780-9]">Navaneethan 2014</a> concluded that clotrimazole was not superior to other azoles in their studies. However, <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> found that topical fluconazole was superior to clotrimazole. The I<sup>2</sup> value in our pooled analysis was 86%, indicating significant heterogeneity. We also discovered considerable variation in clinical resolution with clotrimazole across the studies. This varied from 38% at four weeks (<a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a>) to 86% at three weeks (<a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a>). The reasons for this variation were not clear but it could be due to differences in the baseline characteristics of the population, compliance with treatment or local levels of fungal resistance. We noted that <a href="./references#CD009289-bbs2-0004" title="PrabhakaranP , NavinN , SrinivasanR , PalanisamyT , KanagamuthuP , SomuP , et al. A comparative study of efficacy of clotrimazole and fluconazole ear drops in otomycosis. Journal of Evolution of Medical and Dental Sciences2018;7(17):2058-61. [DOI: 10.14260]">Prabhakaran 2018</a> was the only study that specifically included immunocompromised patients but the exact proportion remains unknown. All of these factors add to the difficulty in drawing meaningful conclusions. </p> </section> <section id="CD009289-sec-0106"> <h4 class="title">Indirectness</h4> <p>We judged <a href="./references#CD009289-bbs2-0001" title="dela Paz CotaB , VegasP , NavarreteJ , MulgadoG , HuertaJ , BautistaE , et al. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. American Journal of Otolaryngology2018;39:307-12. NCT01993823. A phase III, multicenter, randomized, double-blind, parallel group, active treatment-controlled study assessing the safety and efficacy of G238 compared to clotrimazole 1% otic solution in patients with otomycosis. http://clinicaltrials.gov/show/NCT01993823 (first received 25 November 2013). [4291136]">de la Paz Cota 2018</a> to have a lower risk of bias compared to the other studies. However, only participants aged 18 years or older were included. The results from this study may therefore not apply to patients with otomycosis in all age groups. Also, the countries in which these studies originated were restricted to Spain, Mexico and India. This limits the generalisability of the results. </p> <p>Similarly, the overall certainty of the evidence assessed using GRADE for the bifonazole cream versus bifonazole solution comparison (<a href="./references#CD009289-bbs2-0002" title="delPalacioA , Lopez-SusoM , MooreM , CuetaraM , Garcia-La CalleC , NoriegaA . Long term follow-up of otomycosis and its treatment with bifonazole. Journal of Medical and Veterinary Mycology1993;31:435-47. ">del Palacio 1993</a>) was very low, with downgrading in the GRADE domains of study limitations (risk of bias), imprecision (small number of events with narrow confidence intervals) and indirectness (single‐centre study from one country limiting external validity) (<a href="./references#CD009289-bbs2-0043" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Handbook 2011</a>). </p> </section> </section> <section id="CD009289-sec-0107"> <h3 class="title" id="CD009289-sec-0107">Potential biases in the review process</h3> <p>In our search we identified several studies that we classified as ongoing, some of which stated that the recruitment process was completed but their full data were not published. We attempted to contact the persons responsible for these studies for clarification but received no responses. This raises a concern that there may be more studies conducted in a similar way yet unpublished or where the results are available but have not been identified through our searches. </p> </section> <section id="CD009289-sec-0108"> <h3 class="title" id="CD009289-sec-0108">Agreements and disagreements with other studies or reviews</h3> <p>There are few previous systematic reviews or guidelines on the treatment of otomycosis. The World Health Organization (WHO) in 2006 suggested that otomycosis can be treated effectively with a single instillation of 1% silver nitrate gel, repeated after a couple of days if needed (<a href="./references#CD009289-bbs2-0064" title="World Health Organization. Primary Ear and Hearing Care Training Resource: Advanced Level. Geneva: World Health Organization, 2006.">WHO 2006</a>). There was no mention of using azoles. Neither the American Academy of Otolaryngology nor the <i>BMJ Best Practice</i> has published guidance on otomycosis. </p> <p>One published systematic review compared Locacorten‐Vioform and clotrimazole for otomycosis. Although the review found both to be safe and effective, the authors concluded that there is insufficient evidence to support increased efficacy of either drug (<a href="./references#CD009289-bbs2-0045" title="HerasymK , BonaparteJ , KiltyS . A comparison of Locacorten-Vioform and clotrimazole in otomycosis: a systematic review and one-way meta-analysis. Laryngoscope2016;126:1411-9.">Herasym 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009289-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/urn:x-wiley:14651858:media:CD009289:CD009289-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Process for sifting search results and selecting studies for inclusion." data-id="CD009289-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_t/tCD009289-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Process for sifting search results and selecting studies for inclusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009289-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/urn:x-wiley:14651858:media:CD009289:CD009289-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009289-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_t/tCD009289-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009289-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/urn:x-wiley:14651858:media:CD009289:CD009289-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009289-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_t/tCD009289-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009289-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/urn:x-wiley:14651858:media:CD009289:CD009289-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Clotrimazole versus another azole, Outcome 1: Complete clinical resolution at 2 to 4 weeks" data-id="CD009289-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_t/tCD009289-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Clotrimazole versus another azole, Outcome 1: Complete clinical resolution at 2 to 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references#CD009289-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009289-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/urn:x-wiley:14651858:media:CD009289:CD009289-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Clotrimazole versus another azole, Outcome 2: Mycological cure" data-id="CD009289-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_t/tCD009289-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Clotrimazole versus another azole, Outcome 2: Mycological cure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references#CD009289-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009289-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/urn:x-wiley:14651858:media:CD009289:CD009289-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Clotrimazole versus another azole, Outcome 3: Other adverse events" data-id="CD009289-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_t/tCD009289-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Clotrimazole versus another azole, Outcome 3: Other adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references#CD009289-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/media/CDSR/CD009289/image_n/nCD009289-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009289-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Clotrimazole compared to another azole for otomycosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Clotrimazole compared to another azole for otomycosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Patient or population:</b> patients with otomycosis<br/><b>Setting:</b> ENT clinics<br/><b>Intervention:</b> clotrimazole<br/><b>Comparison:</b> another azole </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with another azole</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with clotrimazole</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Complete clinical resolution</p> <p>Follow‐up: range 2 to 4 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.59 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>439<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is very uncertain whether there is a difference between clotrimazole and other azoles at achieving complete clinical resolution at 4 weeks. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>835 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>668 per 1000<br/>(492 per 1000 to 893 per 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant adverse events</p> <p>Follow‐up: 24 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The only study that mentioned significant adverse events reported that there were no events in either group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to the lack of events and low number of participants it is very uncertain whether there is a difference between the groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mycological resolution</p> <p>Follow‐up: 24 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.96 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>174<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clotrimazole may result in little or no difference in mycological outcomes at 24‐day follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>966 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>976 per 1000<br/>(928 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Other adverse events</p> <p>Follow‐up: 24 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/>(0.18 to 3.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>174<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is very uncertain whether there is a difference between clotrimazole and other azoles in non‐significant adverse events at 24 days follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(8 to 153) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded to very low‐certainty evidence: downgraded by one level due to study limitations (risk of bias) because there was unclear allocation concealment, attrition bias and selective reporting bias. Downgraded by one level for inconsistency (heterogeneity of results; I<sup>2</sup> = 86%). Downgraded by one level for imprecision (confidence interval includes the possibility of both no difference and a substantial reduction in clinical resolution with clotrimazole). </p> <p><sup>2</sup>Downgraded to low‐certainty evidence. Downgraded by one level for indirectness (participants under 18 years old were excluded). Downgraded by two levels for imprecision (small sample size and no events reported, therefore unable to calculate an effect size). </p> <p><sup>3</sup>Downgraded to low‐certainty evidence. Downgraded by one level for indirectness (participants under 18 years old were excluded). Downgraded by one level for imprecision (small sample size). </p> <p><sup>4</sup>Downgraded to very low‐certainty evidence. Downgraded by one level for indirectness (participants under 18 years old were excluded). Downgraded by two levels for imprecision (low number of events, small sample size and very wide confidence intervals that include the possibility of either substantial benefit or substantial harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Clotrimazole compared to another azole for otomycosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009289-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of agents used to treat fungal infections</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Class of antifungals</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Examples</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mechanism of action</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bifonazole, clotrimazole, eberconazole, fluconazole, miconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits the synthesis of ergosterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyenes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nystatin, amphotericin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interacts with fungal membrane sterols</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nucleoside analogues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flucytosine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits macromolecular synthesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Echinocandins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caspofungin, micafungin, anidulafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits fungal cell wall synthesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antiseptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boric acid, gentian violet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydroxyquinolines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clioquinol (in Locacorten‐Vioform)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inhibits fungal cell wall synthesis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>From <a href="./references#CD009289-bbs2-0055" title="MunguiaR , DanielS . Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otolaryngology2008;72(4):453-9.">Munguia 2008</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classes of agents used to treat fungal infections</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/full#CD009289-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009289-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clotrimazole versus another azole</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Complete clinical resolution at 2 to 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mycological cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.18, 3.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clotrimazole versus another azole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009289.pub2/references#CD009289-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009289.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009289-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009289-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009289-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009289-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD009289-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009289-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009289-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009289-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009289-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009289\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009289\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009289\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009289\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009289\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009289.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009289.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009289.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009289.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009289.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724381233"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009289.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724381237"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009289.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e617069eef3fd',t:'MTc0MDcyNDM4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 